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tal and physical component summary (MCS, PCS) and SF-6D (health utility) scores), 
productivity loss (Work Productivity and Activity Impairment questionnaire) and 
healthcare utilization in the past 6 months. Multivariable analyses were performed 
to adjust for baseline differences (e.g., age, gender, ethnicity, household income, 
insurance status, comorbidity burden, etc.). RESULTS: Among respondents with 
T2DM (n= 7,066; 39.5% female; 60.0 years), 63.0% were obese, 23.0% had SD, and 17.4% 
had obesity and SD. Multivariable analyses showed significantly worsening health 
status and greater productivity loss and healthcare utilization among respondents 
with T2DM who also had obesity or SD, or both. Respondents with T2DM/Obesity/
SD reported the poorest outcomes (vs. T2DM only): lower MCS (43.9 vs. 51.1), PCS 
(39.1 vs. 47.1), health utilities (0.62 vs. 0.73), greater absenteeism (5.5% vs. 2.0%), 
presenteeism (26.9% vs. 10.9%), overall work impairment (30.0% vs. 12.6%), activity 
impairment (43.5% vs. 21.9%), provider visits (7.7 vs. 4.6), and emergency room visits 
(0.29 vs. 0.16), all p< 0.05. CONCLUSIONS: Majority of respondents with T2DM and 
SD were obese, suggesting a strong link between obesity and SD. Coexistence of 
obesity and SD led to significantly negative impact on health status, productivity, 
and healthcare utilization in patients with T2DM. Interventions focusing on SD and 
obesity may be clinically and economically beneficial.
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OBJECTIVES: For patients with type 2 diabetes (T2DM), achieving optimal levels of 
hemoglobin A1c (HbA1c), blood pressure (BP), and LDL-cholesterol (LDL-C), or the 
“ABCs” of diabetes, has been linked to several health benefits, but goal attainment 
rates in the United States remain low. This study sought to determine how ABC goal 
attainment is associated with the presence of major depressive disorder (MDD) 
and Health-Related Quality of Life (HRQoL) among a national sample of patients 
with T2DM. METHODS: This study was a retrospective analysis of the National 
Health and Nutrition Examination Survey (NHANES) data from 2007-2012. Primary 
endpoints for ABC goal attainment were defined as HbA1c < 7%, BP < 130/80mmHg, 
and LDL-C < 100mg/dL. The study sample consisted of non-pregnant participants at 
least 20 years old with T2DM, stratified by presence of MDD. Comparisons between 
individuals who achieved and were unable to achieve simultaneous ABC goals were 
conducted using t-tests or chi-square analyses as appropriate. Multivariate logis-
tic regression was used to analyze which factors potentially influence ABC goal 
achievement. RESULTS: A total of 808 participants with T2DM met the inclusion 
criteria. The mean age for all participants was 60.5 years and 51.4% were female. 
Based on Patient Health Questionnaire (PHQ-9) scores, 11.63% of participants met 
the criteria for MDD. Overall, 23.7% of total participants were at goal for all 3 ABC 
parameters, with no significant difference in goal attainment between patients with 
or without MDD. Participants with T2DM and meeting criteria for MDD reported 
poorer general health, poorer physical health, and poorer mental health (p< 0.001 
for all) than those who did not meet criteria for MDD, according to results from the 
HRQoL survey. CONCLUSIONS: Among the study population with T2DM, presence 
of MDD showed no significant impact on ABC goal attainment. However, presence 
of MDD had a positive association with poor HRQoL.
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OBJECTIVES: Few indirect comparisons have been performed examining health-
related quality of life (HRQoL) data, owing in part to paucity of data collection. As 
health care delivery becomes increasingly patient-centered, examining HRQoL out-
comes with these methods will become important for decision making. This analysis 
utilized indirect comparison methods to assess differences in Impact of Weight on 
Quality of Life – Lite (IWQoL-Lite) total score for canagliflozin (CANA), compared 
to exenatide QW (ExQW), sitagliptin (SITA), and pioglitazone (PIO), using trial data 
evaluating these agents as add-on to metformin. METHODS: Published results 
from the DURATION-2 trial of ExQW compared to PIO and SITA, and subject-level 
data from a trial comparing CANA to SITA (DIA3006), were available for analyses. 
Disease characteristics and baseline IWQoL-Lite scores were similar, and both trials 
assessed change in IWQoL-Lite total score from baseline to Week 26. Bayesian fixed-
effect models with non-informative priors were used to estimate the difference in 
IWQoL-Lite total score for CANA (100 and 300 mg, pooled) versus ExQW, SITA, and 
PIO. Analyses were also performed to test the robustness of these results, including 
those that adjusted for potential determinants of HRQoL. RESULTS: In the unad-
justed analysis, the probability that CANA is better than ExQW, SITA, and PIO was 
60.0% (median difference [95% CrI]: –0.43 [–2.84, 3.62]), 89.9% (1.02 [–0.55, 2.58]), and 
99.5% (4.36 [1.06, 7.64]). Restricted to DURATION-2 inclusion and exclusion criteria, 
the probabilities were 61.6%, 82.1%, and 98.9%, respectively. Further adjustment 
for race and country differences yielded probabilities of 74.6% versus ExQW, 85.9% 
versus SITA, and 98.5% versus PIO. CONCLUSIONS: The adjusted analyses suggest 
that CANA is associated with at least similar IWQoL-Lite change scores compared 
to ExQW and greater improvements in IWQoL-Lite score compared to SITA and PIO. 
These analyses illustrate that indirect comparisons of HRQoL data should explore 
potential determinants of HRQoL.
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(48%), and energy/activity level (36%) for Physical; juvenalization (51%) and teasing/
bullying (33%) for Social; and self-confidence (45%) and worry (34%) for Emotional. 
Emotional and social impacts were often related to others’ perception or treat-
ment of the child as younger, and all impacts were moderated by physical growth. 
Additionally, children who began treatment later in life experienced more emotional 
and social impacts than children who started treatment at an earlier age. Children 
and caregivers reported consistent symptoms/impacts. Modifiers to the degree of 
impact of GHD were identified and include age at treatment, growth velocity, and 
having other children in family with GHD. Responses did not differ substantially 
among countries. CONCLUSIONS: Concept elicitation of the burden of disease for 
children with GHD identified key concepts that should be included in PRO/ObsRO 
measures to assess the impact of GHD and treatment.
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OBJECTIVES: To identify and compare the health outcomes profiles of adults receiv-
ing medical care at specialty clinics for symptomatic (chronic pain) and largely 
asymptomatic (diabetes) chronic conditions. METHODS: Patients receiving care at 
pain or diabetes clinic completed the PROMIS-29 instrument that measures 7 health 
domains. Item response theory-based scores are on the T-metric with a mean of 50 
and standard deviation (SD) of 10 based on the general United States population 
(norm). RESULTS: A total of 227 patients participated in the study (n= 128 chronic 
pain; n= 99 diabetes). The mean age was 46.7years (SD= 13.7), 56% were women, 
86.9% were non-Hispanic white, and 31.2% had < = 12 years of education. Pain clinic 
patients were significantly older and less educated than diabetes clinic patients, 
however there were no other demographic differences between patient groups. All 
7 domain scores were statistically significantly worse for the chronic pain clinic 
patients compared with diabetes clinic patients (P< 0.001 for all comparisons). 
The smallest and largest differences between clinics were observed for anxiety 
(mean difference= 11.4) and pain interference (mean difference= 22.0), respectively. 
Adjustment for age, sex, and education only slightly attenuated differences between 
the two patient populations. For example, the unadjusted mean difference between 
diagnostic groups for physical function was 17.7 (P< 0.001), while the mean differ-
ence was 16.02 (P< 0.001) when adjusted for demographic characteristics. The pain 
clinic sample had mean scores that were 0.9 to 1.7 SDs worse than the norm on all 
domains. CONCLUSIONS: Compared with patients with diabetes, chronic pain clinic 
patients had a substantially poorer PROMIS-29 health outcome profile. Findings indi-
cate that not only are health outcome profiles for chronic pain patients poor relative 
to the US population, but also poor relative to patients with a different chronic but 
relatively asymptomatic condition (diabetes) suggesting that aversive symptoms 
may have a more significant impact than chronic disease per se.
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OBJECTIVES: To measure the mental well-being experienced by patients with 
type 2 diabetes (T2D) by utilizing the SF-36v2 mental component summary 
(MCS). METHODS: Data were from the 2013 U.S. National Health and Wellness 
Survey. Respondents (aged ≥ 18 years) provided details about their health status 
and health care through self-administered, Internet-based questionnaires. The 
analytic sample included those self-reporting a T2D diagnosis. Mental well-being 
was defined by utilizing the SF-36v2 MCS. Based on the normed mean of 50 and 
standard deviation (SD) of 10 for the general population and the distribution of 
MCS scores within the analytic sample, categories were defined as good mental 
well-being (above the population mean; MCS ≥ 50), poor mental well-being (≤ 1 SD 
below the population mean; MCS ≥ 40 and < 50), and very poor mental well-being (> 1 
SD below the population mean; MCS< 40). RESULTS: The analytic sample consisted 
of 7852 respondents diagnosed with T2D. Of these, 22% (n= 1701) experienced very 
poor mental well-being, 23% (n= 1781) poor mental well-being, and 56% (n= 4370) 
good mental well-being. Very poor/poor mental well-being was associated with 
respondents who were younger, female, non-white, less educated, current smokers, 
and had lower household income (p< 0.001 for all). Respondents with very poor/poor 
mental well-being vs. good mental well-being had greater Charlson Comorbidity 
Index scores (mean of 1.99/1.77 vs. 1.59), and were more likely to be diagnosed with 
depression (57%/26% vs. 5%) or an anxiety disorder (44%/20% vs. 5%) (p< 0.001 for 
all). Poorer mental well-being also was associated with having T2D for a shorter 
period of time, use of insulin, experience with hypoglycemia, and greater likelihood 
of T2D related complications (p< 0.001 for all). CONCLUSIONS: Poorer mental well-
being, as measured by the SF-36v2 MCS, is associated with greater overall physical 
and psychiatric morbidity, as well as morbidity specifically associated with T2D.
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OBJECTIVES: Obesity is a strong risk factor for sleep disorders (SD) and type 2 dia-
betes mellitus (T2DM). SD and T2DM are often associated. This study examined the 
incremental burden of obesity and SD in patients with T2DM. METHODS: Data were 
analyzed from the 2012 US National Health and Wellness Survey, a nationally repre-
sentative, online survey of 71,157 adults (≥ 18 years). Respondents with T2DM were 
categorized into 4 groups: T2DM only; T2DM with obesity; T2DM with SD; T2DM with 
obesity and SD. Respondents provided information on health status (SF-36v2: men-
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co-morbidities. No statistically significant association was observed between CPG 
2009 adherence and co-morbidities. CONCLUSIONS: The study explored the various 
aspects of prescribing pattern of physicians, their adherence to the CPG 2009 and 
the management of DM with other co-morbidities. This study also recognized the 
need for improvement in prescribers’ pattern of prescription and DM management 
with co-morbidities.
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OBJECTIVES: To compare the pivotal clinical endpoints on the prescribing informa-
tion labels of next generation treatments for type 2 diabetes (T2D) and to identify 
the most clinically-relevant antidiabetic outcomes. This multivariate analysis was 
designed to identify the appropriate treatment paradigm for the management of 
patients with T2D, based on symptomatology and relative efficacy. METHODS: 
A multivariate analysis of clinical efficacy endpoints from product information 
labels of 10 recently approved next generation treatments for adult T2D was under-
taken, with 26-week, placebo-controlled endpoint data for utilized all compounds, 
including change from baseline in hemoglobin A1c (%), body weight (kg), fasting 
plasma glucose (mg/dL), post-prandial plasma glucose (mg/dL), and the incidence 
of hypoglycemic events (%). Clinical relevance for this analysis was defined as 1% 
reduction in HbA1c, 5kg reduction in mean body weight from baseline, and an 
incidence of hypoglycemia < 1%. Data with metformin in combination therapy was 
included where available, based on current therapeutic guidelines. RESULTS: The 
multivariate analysis highlighted that no single compound met the predefined 
hypothesis of clinical relevance after 26-weeks of treatment. Canagliflozin 300mg 
/ metformin (-1.06%) and liraglutide (-1.00%) reported the greatest reduction in 
HbA1c. Canagliflozin 300mg / metformin (-4.07kg) and dapaglaflozin 10mg / met-
formin (-2.86kg) had the greatest mean reduction in body weight from baseline. 
Linagliptin 5mg / metformin (0.60%) and dapaglaflozin 10mg / metformin (1.10%) 
had the lowest incidence of hypoglycemia. CONCLUSIONS: Physicians should con-
sider all clinically-relevant outcomes of available T2D therapies with individual 
patient needs before initiating treatment. Clinicians must be aware of the various 
clinical outcomes for available therapies to ensure a safe and effective treatment 
regimen based on the symptomatic profile of individual patients. A triple-goal tar-
geted approach to the management of T2D may reduce healthcare costs and treat-
ment augmentation while improving quality of life for patients.
PDB90
meDIcatIon utIlIzatIon Pattern for PaIn manaGement amonG 
InDIvIDuals wItH tyPe 2 DIaBetes
Atreja N, Fleming M
University of Houston, Houston, TX, USA
OBJECTIVES: Various medications are commonly used to treat pain among indi-
viduals with type 2 diabetes mellitus (T2DM). This study examined the drug uti-
lization trends and factors associated with the use of pain medications among 
patients diagnosed with T2DM. METHODS: Data from the National Ambulatory 
Care Survey (NAMCS) 2006-2010 and the outpatient department component of the 
National Hospital Ambulatory Medical Care Survey (NHAMCS) were used to examine 
diabetes-related ambulatory visits among patients with T2DM. Bivariate chi-square 
analysis and multiple logistic regression were performed to evaluate the factors 
associated with prescribing of pain medications (e.g., anticonvulsants, antidepres-
sants, opioids and some topical agents). SAS survey procedures that adjust for the 
complex sampling procedure of NAMCS and NHAMCS were used. RESULTS: An 
average of 50 million (4.63%) visits was made by patients with T2DM from 2006 to 
2010. The majority of visits were made by females (54.84%), Whites (69.80%) and 
individuals aged 45-64 years (47.66%). Among patients with T2DM, 9.70% were pre-
scribed pain management drugs. The most commonly prescribed pain management 
drugs were anticonvulsants (4.51%), antidepressants (2.80%) and opioids (2.30%). 
Multiple logistic regression analysis showed that females (OR: 1.48; 95% CI: 1.19-
1.82), number of physician visits greater than 1 (OR: 1.39; 95% CI: 1.32-1.46), having 
private insurance (OR: 0.67; 95% CI: 0.49-0.90), and endocrinologist visit (OR: 0.68; 
95% CI: 0.51-0.89) are significant predictors of pain medication use among T2DM 
patients. CONCLUSIONS: Patients with T2DM were prescribed anticonvulsants two 
times more often as compared to opioids for pain management. Dispensed pre-
scriptions for pain medications were related to gender and number of physician 
visits. More frequent pain management related visits from patients over age 65 was 
consistent with the literature. Endocrinologist are less likely to prescribe medication 
for pain management than general medicine specialists.
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OBJECTIVES: To compare time to discontinuation with canagliflozin versus DPP-4 
inhibitors and GLP-1 agonists in patients with T2DM using retrospective claims 
data. METHODS: Patients with T2DM who received a first prescription for a DPP-4 
inhibitor (sitagliptin, saxagliptin, linagliptin), GLP-1 agonist (liraglutide, exenatide, 
exenatide long-acting), or an agent that inhibits SGLT2 (canagliflozin) in 2013 
were extracted from two US claims databases of commercially insured patients 
(Truven, Optum).  The analytical sample included only patients with ≥6 months 
of retrospective data prior to their first paid claim.  Discontinuation was defined 
as an observed refill gap ≥90 days (sensitivity analysis for 30/60 days) between 
BACKGROUND: Previous findings regarding the effect of depression treatment and 
its consequences on health related quality of life (HRQoL) of adults with diabetes 
were inconsistent and targeted certain groups of population. Therefore, there is 
a critical need to perform a study that focuses on a general population with dia-
betes and depression. OBJECTIVES: The primary aim of this study is to examine 
the physical and mental HRQoL associated with depression treatment. METHODS: 
We adopted a longitudinal design using multiple panels (2005-2011) of Medical 
Expenditure Panel Survey to create one year of baseline and one year of follow-
up. We categorized baseline depression treatment into no depression treatment, 
antidepressant use only and psychotherapy with or without antidepressants. We 
used perceived physical and mental health status during the follow-up year as 
measurements of HRQoL. Chi- square tests and multinomial logistic regressions 
were used to examine the association between depression treatment categories 
and HRQoL measures. In the adjusted analysis, we controlled for socio-demographic 
factors, lifestyle risk factors, other chronic conditions, and the baseline HRQoL 
measures. RESULTS: A significant association was observed between depression 
treatment and physical HRQoL measure in both unadjusted and adjusted models. 
Among adults who received psychotherapy (with or without antidepressants) 17.7% 
reported excellent /very good physical HRQoL while only 9.3% of those without 
depression treatment did so. In adjusted analyses, adults who received psycho-
therapy (with or without antidepressants) were more likely to report excellent/ very 
good health compared to those without depression treatment [adjusted OR = 2.32, 
95% CI = 1.01, 5.34]. For mental HRQoL, no significant differences were observed 
between treatment groups in the adjusted model. CONCLUSIONS: Depression treat-
ment, especially psychotherapy (with or without antidepressants) may improve 
physical HRQoL.
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OBJECTIVES: The aim of this study was to determine patient benefit-risk preference 
of insulin treatment, and to examine how preference is predicted by health literacy, 
sociodemographic status and patients own health risk perception. As a secondary 
objective we investigated whether elicited preferences were sensitive to the pres-
entation of benefits as either a surrogate or clinical health outcome METHODS: 
This was a questionnaire based study involving Danish type 2 diabetes patients 
recruited through a diabetes registry. Laboratory- and clinical data on diabetes 
management status was obtained from the registry. The questionnaire included 
a section on diabetes management, health literacy, demographics and a discrete 
choice experiment (DCE). In the DCE, respondents were asked to choose between 
two unlabelled insulin treatments. These were defined by improvements in glucose 
control (HbA1c or long-term sequelae risk reduction), weight control, hypoglycemic 
events (severe/minor) and treatment-related heart attack risk. A Baysian efficient 
design (Ngene v 1.1.1) was used to construct the choice tasks. Logistic regression 
analysis was used to describe the data relationships. Regression coefficients derived 
from this model were used to estimate maximum acceptable risk (MAR) of treatment 
in return of benefit. RESULTS: One thousand and thirty-three patients completed 
the questionnaire. Overall, the avoidance of a minor increase in heart-attack risk 
(3 additional people of 1000) was driving choice of treatment across all versions of 
the DCE. This was followed by avoiding severe hypoglycemic events. We observe 
some differences in preference estimates across the DCE versions indicating that 
patients are sensitive to the presentation of benefit as long-term sequelae risk 
reduction rather than a surrogate measure of health improvement (HbA1c). Detailed 
results on subgroup analysis and predictors of preference are presented at the 
conference. CONCLUSIONS: Risk-aversion of heart attack, although it is a minor 
additional risk, influence patient choice of treatment. Final conclusion is presented 
at the conference.
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OBJECTIVES: To evaluate the prescription pattern, adherence of prescribers with 
Clinical Practice Guideline 2009 and management of diabetes mellitus (DM) with co-
morbidities in a tertiary-care hospital, Pinang General Hospital Malaysia. METHODS: 
Cross-sectional study was performed on a total 51 prescribers and 1020 patients’ 
prescriptions written by the same prescribers (20 prescriptions for each prescriber). 
All 1020 DM patients were suffered with other co-morbidities. All of the prescrip-
tions were divided into two different groups i.e. adherent and non-adherent 
prescriptions. Self-administered research tools were used and demographic charac-
teristics of the patients were determined by descriptive statistics. Data was analyzed 
by using SPSS 21.0. Comparison between adherent and non-adherent groups was 
done by inferential statistics. RESULTS: In all prescriptions, overall good level of 
physician adherence was seen with respect to the recommendations of CPG 2009. A 
statistically significant negative association (Ф= 0.094, p-value= 0.003) was observed 
between DM management and co-morbidities. CPG adherent had shown statisti-
cally weak negative association (Ф= - 0.081, p-value= 0.010) with patients having 
